The vulnerability of our society to life-threatening emerging viruses with epidemic potential is largely due to the lack of appropriate preparedness including access to an effective prophylactic and therapeutic mean to protect the population. We aim to develop an innovative treatment strategy based on the broad-spectrum antiviral drug Favipiravir. The drug will be tested for the first time in human healthy volunteers given orally to evaluate its safety at high doses and its potential to achieve high level of protection against HFV and other emerging RNA viruses. We will employ mathematical modelling techniques to integrate these data with our current knowledge on Favipiravir efficacy to propose individualized treatment strategy that can provide protection and/or high chance of cure against highly pathogenic viruses.